VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
BHC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
BHCBausch Health Companies Inc.
$5.71$2.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. BHC
  4. Financial Ratios

Bausch Health Companies Inc. (BHC) Financial Ratios

Latest Ratios: P/E Ratio 13.3x · EV/EBITDA 6.4x · ROE 588.2%. (1996–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

BHC Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$2.1B$2.6B$3.0B$2.9B$2.3B$9.9B$7.4B$10.5B$6.5B$7.3B$5.0B
Enterprise Value$22.0B$22.5B$23.6B$24.4B$22.5B$32.0B$30.7B$33.2B$30.0B$32.0B$34.3B
P/E Ratio →13.2816.16———————2.42—
P/S Ratio0.200.250.310.330.281.170.921.220.770.840.52
P/B Ratio5.696.93——8.74—12.209.272.301.231.55
P/FCF2.132.602.353.85—8.679.218.615.103.742.81
P/OCF1.521.861.862.84—6.956.657.024.313.192.42

P/E links to full P/E history page with 30-year chart

BHC EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—2.152.452.782.773.793.833.863.593.673.55
EV / EBITDA6.386.518.3910.9412.1615.9712.2817.7369.0710.8214.93
EV / EBIT9.9011.1612.6515.0315.1518.7223.3824.7360.0957.7228.50
EV / FCF—22.4218.7432.06—27.9838.2827.1423.7316.3919.12

BHC Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin60.9%60.9%71.1%70.8%70.9%71.6%72.0%72.7%71.9%70.8%73.4%
Operating Margin21.3%21.3%16.1%11.0%5.6%5.3%8.4%-2.4%-28.4%1.2%-5.9%
Net Profit Margin1.5%1.5%-0.5%-6.8%-2.8%-11.2%-7.0%-20.7%-49.5%27.6%-24.9%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE588.2%588.2%—-665.2%-199.1%-332.0%-64.2%-90.3%-94.7%52.2%-51.9%
ROA0.6%0.6%-0.2%-2.2%-0.8%-3.1%-1.7%-5.8%-12.8%5.9%-5.2%
ROIC8.2%8.2%5.6%3.5%1.6%1.5%2.1%-0.6%-6.3%0.2%-1.2%
ROCE10.6%10.6%7.2%4.3%2.0%1.8%2.5%-0.8%-8.4%0.3%-1.4%

BHC Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity56.3656.36——79.87—39.5522.798.634.289.16
Debt / EBITDA6.146.147.7610.0511.2411.329.5713.8355.878.6012.98
Net Debt / Equity—52.84——77.70—38.5519.948.384.168.99
Net Debt / EBITDA5.765.767.349.6310.9311.029.3212.1054.228.3512.74
Debt / FCF—19.8316.3828.21—19.3129.0818.5218.6312.6516.32
Interest Coverage1.231.231.351.221.011.200.860.830.300.300.66

BHC Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio1.471.470.861.301.081.081.091.120.191.111.41
Quick Ratio1.081.080.620.940.800.890.860.94-0.060.871.11
Cash Ratio0.320.320.170.220.140.110.120.520.190.170.15
Asset Turnover—0.400.360.320.320.290.260.250.310.230.22
Inventory Turnover2.512.511.741.662.172.412.062.122.522.432.43
Days Sales Outstanding—82.0081.1583.2880.4276.8271.7178.0481.2389.1294.97

BHC Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield7.5%6.2%———————41.3%—
FCF Yield47.0%38.5%42.5%26.0%—11.5%10.9%11.6%19.6%26.7%35.6%
Buyback Yield0.0%0.0%0.9%0.0%0.0%0.0%0.0%0.4%0.2%0.1%0.2%
Total Shareholder Yield0.0%0.0%0.9%0.0%0.0%0.0%0.0%0.4%0.2%0.1%0.2%
Shares Outstanding—$375M$368M$365M$362M$359M$355M$352M$350M$352M$347M

Key Metrics

Growth RegimeMixed
ProfitabilityStable
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

Debt burden and revenue volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Margin Spike Masks Underlying Volatility

BHC's gross margin surged to 99.0% in 2026Q2 from 61.2% in 2026Q1, per reported figures, yet operating margin averaged 22.5% over the prior four quarters, indicating the spike is likely non-recurring.

The 2026Q2 gross margin of 99.0% is an outlier relative to the 57-72% range seen in the preceding nine quarters, suggesting a one-time revenue mix shift or accounting adjustment rather than a sustainable improvement. Operating margin of 40.2% in the same quarter contrasts sharply with the 12-27% range in earlier periods, implying that core profitability remains far lower. Investors should monitor whether the elevated margins persist, as the prior income statement analysis flagged similar anomalies.

ROIC Recovery but Still Subpar

ROIC improved to 6.3% in 2026Q2 from 1.0% in 2026Q1, per financial statements, yet it remains below the cost of capital and well under the 8.2% peer average for Prestige Consumer Healthcare.

The sequential ROIC jump is driven by the anomalous margin spike, not by a fundamental improvement in capital efficiency, as asset turnover has stayed flat at 0.07-0.11 over the period. ROE swung wildly from -31.1% in 2025Q4 to 102.4% in 2025Q2, reflecting negative equity rather than genuine value creation. Based on reported figures, BHC's returns on capital are insufficient to cover its debt burden, suggesting ongoing value destruction unless margins stabilize.

Working Capital Cycle Lengthens

BHC's cash conversion cycle extended to 177 days in 2026Q1 from 165 days in 2025Q4, per reported data, driven by DSO of 82 days and DIO of 150 days, indicating slower cash recovery from sales.

The CCC has hovered between 164 and 215 days over the past ten quarters, with DIO notably high at 150-226 days, reflecting inventory-heavy operations that tie up cash. DPO has remained relatively stable around 53-97 days, suggesting limited supplier leverage. The 2026Q2 data for working capital metrics is unavailable, but the prior trend indicates that efficiency gains are elusive, and the liquidity squeeze in that quarter may be partly attributable to this prolonged cycle.

Debt Metrics Distorted by Equity Erosion

D/EBITDA fell to 0.85 in 2026Q2 from 25.84 in 2026Q1, per reported figures, but this reflects a sharp drop in total debt to $866M, likely due to reclassification, while interest coverage remains thin at 1.87.

The reported debt reduction appears inconsistent with the prior balance sheet analysis, which noted total debt near $21B through 2025, suggesting the 2026Q2 figure may not represent a true deleveraging. Interest coverage of 1.87 in 2026Q2 is barely above the 1.0-1.5 range seen in earlier quarters, indicating that operating income is only marginally sufficient to service interest. Given the negative equity of -$1.8B, leverage ratios based on equity are meaningless, and investors should focus on cash flow coverage of debt.

Liquidity Buffer Collapses

BHC's current ratio plunged to 0.20 in 2026Q2 from 1.32 in 2026Q1, per financial statements, with cash at $900M, suggesting a severe near-term liquidity strain.

The current ratio of 0.20 implies that current liabilities exceed current assets by a wide margin, a dramatic deterioration from the 1.19-1.47 range seen in the prior year. Quick ratio of 0.20 confirms that inventory provides no buffer, as it is already minimal. This liquidity squeeze may force the company to rely on external financing or asset sales, though the reported debt reduction in the same quarter could be related to such actions. The sustainability of operations under this stress warrants close monitoring.

Misapplied EV/EBITDA Multiple

BHC's EV/EBITDA of 6.46 appears cheap, but the metric is distorted by volatile EBITDA and a debt structure that may be understated, per reported figures, making it unreliable for valuation.

The EV/EBITDA multiple is commonly used for leveraged healthcare companies, but BHC's EBITDA has swung sharply due to one-time items and margin anomalies, as seen in the 2026Q2 gross margin spike. Additionally, the reported drop in total debt to $866M in 2026Q2, if not a true extinguishment, would understate EV and artificially lower the multiple. A more appropriate metric would be EV/EBITDAR or a normalized EBITDA that excludes non-recurring gains, or a cash-flow-based multiple like EV/OCF, which better captures the company's actual cash generation.

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

Consensus & Technical Research Suite
Open BHC Terminal

BHC Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

BHC — Frequently Asked Questions

Quick answers to the most common questions about buying BHC stock.

What is Bausch Health Companies Inc.'s P/E ratio?

Bausch Health Companies Inc.'s current P/E ratio is 13.3x. The historical average is 25.5x. This places it at the 31th percentile of its historical range.

What is Bausch Health Companies Inc.'s EV/EBITDA?

Bausch Health Companies Inc.'s current EV/EBITDA is 6.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 20.6x.

What is Bausch Health Companies Inc.'s ROE?

Bausch Health Companies Inc.'s return on equity (ROE) is 588.2%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -17.6%.

Is BHC stock overvalued?

Based on historical data, Bausch Health Companies Inc. is trading at a P/E of 13.3x. This is at the 31th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Bausch Health Companies Inc.'s profit margins?

Bausch Health Companies Inc. has 60.9% gross margin and 21.3% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.

How much debt does Bausch Health Companies Inc. have?

Bausch Health Companies Inc.'s Debt/EBITDA ratio is 6.1x, indicating high leverage. A ratio above 4x may signal elevated financial risk.